These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 17267327)

  • 61. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer.
    Pollack A; Wu CS; Czerniak B; Zagars GK; Benedict WF; McDonnell TJ
    Clin Cancer Res; 1997 Oct; 3(10):1823-9. PubMed ID: 9815569
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness.
    Shariat SF; Zlotta AR; Ashfaq R; Sagalowsky AI; Lotan Y
    Mod Pathol; 2007 Apr; 20(4):445-59. PubMed ID: 17384651
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer.
    Stein JP; Penson DF; Lee C; Cai J; Miranda G; Skinner DG
    J Urol; 2009 May; 181(5):2052-8; discussion 2058-9. PubMed ID: 19286213
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer.
    Xi RC; Sheng YR; Chen WH; Sheng L; Gang JJ; Tong Z; Shan Z; Ying GH; Dong LC
    J Surg Oncol; 2013 Apr; 107(5):550-4. PubMed ID: 23090902
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes.
    Moschini M; Shariat SF; Abufaraj M; Soria F; Klatte T; Croce G; Mattei A; Damiano R; Salonia A; Montorsi F; Briganti A; Colombo R; Gallina A
    Urol Oncol; 2017 Apr; 35(4):151.e17-151.e23. PubMed ID: 27932269
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors].
    Ramos Soler D; Navarro Fos S; Villamón Fort R; Gil Salom M; Llombart Bosch A
    Arch Esp Urol; 2003 Apr; 56(3):277-85. PubMed ID: 12768988
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer.
    Swana HS; Grossman D; Anthony JN; Weiss RM; Altieri DC
    N Engl J Med; 1999 Aug; 341(6):452-3. PubMed ID: 10438269
    [No Abstract]   [Full Text] [Related]  

  • 68. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer.
    Fristrup N; Ulhøi BP; Birkenkamp-Demtröder K; Mansilla F; Sanchez-Carbayo M; Segersten U; Malmström PU; Hartmann A; Palou J; Alvarez-Múgica M; Zieger K; Borre M; Ørntoft TF; Dyrskjøt L
    Am J Pathol; 2012 May; 180(5):1824-34. PubMed ID: 22449953
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Detection of nuclear matrix protein 22 and survivin baseline level in patients after radical cystectomy.
    Dong ZL; Lu ZP; Wang HZ; Zhang LY; Wang ZP; Zhang YF; Ma BL
    Urol Int; 2011; 87(4):445-9. PubMed ID: 22056470
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.
    Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Lerner SP; Sagalowsky AI; Cote RJ; Lotan Y
    J Urol; 2010 Jan; 183(1):68-75. PubMed ID: 19913255
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study.
    Rink M; Chun FK; Dahlem R; Soave A; Minner S; Hansen J; Stoupiec M; Coith C; Kluth LA; Ahyai SA; Friedrich MG; Shariat SF; Fisch M; Pantel K; Riethdorf S
    Eur Urol; 2012 Apr; 61(4):810-7. PubMed ID: 22277196
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer.
    Yip KW; Shi W; Pintilie M; Martin JD; Mocanu JD; Wong D; MacMillan C; Gullane P; O'Sullivan B; Bastianutto C; Liu FF
    Clin Cancer Res; 2006 Oct; 12(19):5726-32. PubMed ID: 17020977
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nomograms provide improved accuracy for predicting survival after radical cystectomy.
    Shariat SF; Karakiewicz PI; Palapattu GS; Amiel GE; Lotan Y; Rogers CG; Vazina A; Bastian PJ; Gupta A; Sagalowsky AI; Schoenberg M; Lerner SP
    Clin Cancer Res; 2006 Nov; 12(22):6663-76. PubMed ID: 17121885
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.
    Rogers CG; Palapattu GS; Shariat SF; Karakiewicz PI; Bastian PJ; Lotan Y; Gupta A; Vazina A; Gilad A; Sagalowsky AI; Lerner SP; Schoenberg MP
    J Urol; 2006 Jun; 175(6):2048-53; discussion 2053. PubMed ID: 16697800
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Can tissue microarray-based analysis of protein expression predict recurrence of stage Ta bladder cancer?
    Gudjónsson S; Bendahl PO; Chebil G; Höglund M; Lindgren D; Lundberg LM; Lövgren K; Fernö M; Månsson W; Liedberg F
    Scand J Urol Nephrol; 2011 Sep; 45(4):270-7. PubMed ID: 21504385
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prognostic significance of survivin, β-catenin and p53 expression in urothelial carcinoma.
    Senol S; Yildirim A; Ceyran B; Uruc F; Zemheri E; Ozkanli S; Akalin I; Ulus I; Caskurlu T; Aydin A
    Bosn J Basic Med Sci; 2015 Aug; 15(4):7-14. PubMed ID: 26614845
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
    Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
    Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
    [TBL] [Abstract][Full Text] [Related]  

  • 79. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder.
    Shariat SF; Pahlavan S; Baseman AG; Brown RM; Green AE; Wheeler TM; Lerner SP
    Urology; 2001 Jan; 57(1):60-5. PubMed ID: 11164145
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification.
    Santos L; Amaro T; Costa C; Pereira S; Bento MJ; Lopes P; Oliveira J; Criado B; Lopes C
    Int J Cancer; 2003 Jun; 105(2):267-72. PubMed ID: 12673690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.